its U.S. Life Sciences Leader since 2002. He currently serves on the board of directors of Corvus Pharmaceuticals, Inc., a biopharmaceutical company, Audentes Therapeutics, Inc., a biotechnology
company, and Symic Bio, a biopharmaceutical company. Mr. Morrison has served on numerous life sciences industry boards, including the Biotechnology Industry Organization (BIO) ECS Board, the Bay Area Bioscience Center, the California Life
Sciences Foundation and the Biotechnology Institute. Mr. Morrison holds a B.S. in Accounting and Finance from the University of California, Berkeley and is a Certified Public Accountant (inactive). Mr. Morrisons qualifications to
serve on our Board of Directors include significant accounting expertise and knowledge of the life sciences industry through his
37-year
career in public accounting serving public and private companies in the
life sciences sector, as well as his experience serving on the board of directors (and certain key standing committees) of other biopharmaceutical companies.
Deval L. Patrick
has served as a member of our Board of Directors since April 2015. In April 2015, Mr. Patrick joined Bain
Capital, LP, where he serves as managing director. From January 2007 to January 2015, Mr. Patrick served as the governor of Massachusetts. Prior to his tenure in government, from 2000 to 2004, Mr. Patrick served as the executive vice
president and general counsel at The Coca-Cola Company. Prior to that, he served as vice president and general counsel at ChevronTexaco Corp. (previously Texaco Inc.), from 1998 to 1999. Mr. Patrick received an A.B. in English and American
Literature from Harvard College and a J.D. from Harvard Law School. Mr. Patricks qualifications to serve on our Board of Directors include his significant experience as a business and government leader with a record of success in solving
complex problems, making strategic investments, managing crises and building teams locally, nationally and internationally.
Mark L.
Perry
has served as a member of our Board of Directors since April 2015. From October 2012 to October 2013, Mr. Perry served as an
entrepreneur-in-residence
at Third Rock Ventures. Since August 2011, he has served on various boards of companies and
non-profit
organizations. In October 2004, Mr. Perry joined Aerovance, Inc., a biopharmaceutical company, as a director, and he served as president and chief executive officer of Aerovance from February
2007 to October 2011. Prior to that, Mr. Perry served as the senior business adviser of Gilead Sciences, Inc., a biopharmaceutical company, from April 2004 to February 2007 and as an executive officer from May 1994 to April 2004, during
which time he served in a variety of capacities, including general counsel, chief financial officer and executive vice president of operations. Earlier in his career, from 1981 to 1994, Mr. Perry served as an attorney at Cooley LLP, and
was a partner of the firm from 1987 to 1994. Mr. Perry currently serves on the board of directors of Nvidia Corporation, a visual computing company, as the lead independent director, and MyoKardia, Inc., a biopharmaceutical company, as the
non-executive
chairman of the board. Mr. Perry received a B.A. in history from the University of California, Berkeley and a J.D. from the University of California,
Davis. Mr. Perrys qualifications to serve on our Board of Directors include more than 30 years of experience serving in professional and management positions in the biotechnology industry, as well as his experience serving on
the board of directors (and certain key standing committees) of other biopharmaceutical companies.
Class I: Directors Currently Serving Until the
2019 Annual Meeting of Stockholders
Ted W. Love, M.D.
has served as our Chief Executive Officer and President since June
2014, and as a member of our Board of Directors since September 2013. From February 2010 to August 2012, Dr. Love served as executive vice president, research and development and technical operations of Onyx Pharmaceuticals, Inc. Prior to that,
from 2001 to January 2009, he served as president, chief executive officer and chairman of Nuvelo, Inc., and previously served as senior vice president, development of Theravance, Inc., from 1998 to 2001. Previously, he spent six years at Genentech,
Inc., where he held a number of senior management positions in medical affairs and product development and served as chairman of Genentechs Product Development Committee. Dr. Love currently serves on the board of directors of Amicus
Therapeutics, Inc., a biotechnology company. Dr. Love holds a B.A. from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and fellowship in cardiology at the Massachusetts General Hospital.
Dr. Loves qualifications to serve on our Board of Directors include his role as our principal executive officer and more than 20 years of broad leadership and management experience in the pharmaceutical industry.
7